Chairman, President, CEO, Fortress Biotech
Dr. Rosenwald has served as Chairman, President & CEO of Fortress Biotech since December 2013 and has served as a member of the Fortress Board of Directors since October 2009. Since 2009, Dr. Rosenwald has served as Co-Portfolio Manager and Partner of Opus Point Partners, LLC ('Opus'), an asset management firm in the life sciences industry. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 23 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and been instrumental in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine.
President & CEO, Journey Medical Corporation
Claude has more than 25 years of experience in commercializing some of the most successful dermatology products in the world. He served as Vice President of Dermatology Sales at Medicis Pharmaceutical Corporation and has held various leadership positions in marketing and sales for therapeutic and aesthetic dermatology. He has executed more than 50 product launches during his career. In 2012, Valeant Pharmaceuticals International Inc., acquired Medicis for approximately $2.6B.
Executive VP of Sales & Marketing
Robert has more than 20 years of experience in pharmaceutical, lab and medical management. In his new role, he will assume overall responsibility for sales, trade and managed care functions. Robert comes to Journey from The Dermatology Alliance where he served as Managing Partner for one of the nation's largest independent physician associations in the specialty of dermatology.
Director of Operations, Journey Medical Corporation
Andrew has 5 years of experience in dermatology pharmaceuticals, working for Medicis and Valeant as a forecasting and analytics expert. At Medicis he assisted with the $455MM acquisition of Graceway Pharmaceuticals LLC and the sell-side $2.6B acquisition of Medicis. He has previous experience in investment banking and financial analysis.